chemical structure of semaglutide CAS 910463-68-2 Manufacturers, Suppliers, Factory Semaglutide intermediate | 1118767-15-9

Wegovy is now also approved to reduce cardiovascular (CV) event risk in people with CV disease who have obesity or are overweight

Wegovy is most effective when combined with a reduced-calorie diet and regular physical activity

If you suspect you have experienced a side effect from any medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app

The exact temperature limit (typically 25C or 30C) and allowable duration vary by product, so check your specific product leaflet or SmPC

The MHRA is reviewing the oral form, with a decision expected towards the end of 2026

Higher-dose or topical formulation (3+ mg/day): 100mg vial lasts ~33 days at 3 mg/day and is the best per-mg value for sustained use